GlassScriptPhysician profile
Elizabeth J Tye
NPI 1013228568
$78,159.28
in general payments reported to CMS, 2019-2025
36 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28K · 2022: $27K · 2023: $7,148 · 2024: $4,766 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $4,063 · Travel and Lodging: $820 · Education: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,335.50 |
| Food and Beverage | $4,062.69 |
| Travel and Lodging | $820.49 |
| Education | $306.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $71,761.40 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $1,647.23 | 2021-2025 | Minimed 780g |
| Horizon Therapeutics Plc | $1,202.87 | 2021-2022 | |
| Amgen INC. | $810.25 | 2021-2025 | Evenity, Tepezza, Repatha |
| Astrazeneca Pharmaceuticals LP | $340.77 | 2021-2024 | Flumist Quadrivalent |
| Bayer Healthcare Pharmaceuticals INC. | $315.55 | 2022-2025 | |
| Abbott Laboratories | $298.58 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $251.31 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $229.15 | 2024-2025 | Korlym |
| Astellas Pharma US INC | $188.12 | 2021-2025 | Veozah, Myrbetriq |
| Radius Health, INC. | $120.00 | 2023-2025 | Tymlos |
| Dexcom, INC. | $107.24 | 2024-2025 | Dexcom G6 Transmitter |
| Corium, LLC | $89.22 | 2023-2024 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $87.97 | 2022 | |
| Ascendis Pharma Endocrinology INC | $79.71 | 2025 | Yorvipath |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $70.44 | 2021-2022 | |
| Exact Sciences Corporation | $69.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ultragenyx Pharmaceutical INC. | $68.87 | 2022-2023 | |
| Kyowa Kirin, INC. | $62.04 | 2023-2024 | Crysvita |
| Sanofi-Aventis U.S. LLC | $45.64 | 2021-2023 | |
| Scilex Pharmaceuticals INC. | $44.77 | 2023 | Ztlido |
| Rhythm Pharmaceuticals, INC. | $31.40 | 2025 | Imcivree |
| Tandem Diabetes Care, INC. | $30.77 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Zealand Pharma US, INC. | $21.32 | 2022 | |
| Baxter Healthcare | $20.32 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.63 | 2021 | |
| Ibsa Pharma INC. | $17.69 | 2023 | Tirosint, Licart |
| Hologic Sales and Service, LLC | $17.63 | 2023 | Aptima |
| Millicent US INC | $16.80 | 2024 | Intrarosa |
| Almatica Pharma LLC | $16.42 | 2021 | |
| Pfizer INC. | $15.53 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $15.45 | 2021 | |
| Irhythm Technologies, INC. | $12.96 | 2023 | Zio Xt Patch |
| Idorsia Pharmaceuticals US INC | $12.91 | 2023 | Quviviq |
| Amarin Pharma, INC. | $11.89 | 2021 | |
| Phathom Pharmaceuticals, INC. | $9.12 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Tye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.